Dear COSTers,

As the Guest Editor of the Special Issue of Pharmaceutics (IF 4.421) “Cancer Nanomedicine—From the Bench to the Bedside” entirely devoted to our Action, it is my pleasure inform you that the dinal deadline for paper submission has been post-poned to the end of August, 2021 in consideration of the ongoing COVID-19 pandemic.

Accordingly, I strongly encourage you to submit an article on any Action-related topic. The article may be either a full paper or a communication based on your own research in this area, or may be a focused review article on some aspect of the subject. All submissions will be subject to peer review. If you plan to submit a review article, please provide me with a title and brief description at your earliest convenience, in order to avoid multiple reviews covering the same material.

Pharmaceutics is fully open access. Open access (unlimited and free access by readers) increases publicity and promotes more frequent citations, as indicated by several studies. Open access is supported by the authors and their institutes. An article processing charge of CHF 2200 (APC) applies to each accepted paper. However, as a Guest Editor I can still offer a discount of 30% for 2 selected papers and an unlimited number of 15% discount for papers submitted within the proposed deadline.

I would strongly appreciate if you could let me know if you are interested in preparing a manuscript for this Special Issue and I will send you more detailed instructions for submission.

Special Issue: Dendrimers for Biomedical Applications
Website: https://www.mdpi.com/journal/pharmaceutics/special_issues/cancer_nanomed
Submission deadline: 31 AUGUST 2021.
 

With the personal best wishes for a Happy and healthy 2021

Your Scientific Dissemination Manager and Action Vice chair

Sabrina Pricl